Bleeding related adverse events associated with antiviral treatment in influenza patients: A disproportionality analysis using FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Sarker, Jyotirmoy [1 ]
Carkovic, Emir [2 ]
Lee, Todd A. [3 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1036
引用
收藏
页码：486 / 487
页数：2
相关论文
共 50 条
  • [1] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [2] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [3] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [4] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [5] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    Drug Safety, 2020, 43 : 607 - 609
  • [7] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Rees, Kate E.
    Chyou, Te-yuan
    Nishtala, Prasad S.
    DRUG SAFETY, 2020, 43 (06) : 607 - 609
  • [8] Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Dai, Zhicheng
    Zhang, Jiafeng
    Tao, Zhengbo
    Gao, Rui
    Zhao, Qinghua
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [9] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [10] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    HELIYON, 2024, 10 (17)
12345